Product Overview

Dapagliflozin 5 mg is a prescription medication classified as a sodium‑glucose cotransporter‑2 SGLT2 inhibitor. Manufactured by Healing Pharma in India each strip contains 10 tablets of 5 mg dapagliflozin a proven adjunct to diet and exercise for adults with type 2 diabetes mellitus. The product is available in pack sizes of 100 200 or 300 tablets offering flexibility for long‑term therapy. This medication helps lower blood glucose by blocking renal glucose reabsorption thereby promoting urinary glucose excretion. It is supplied in a standard 10‑tablet strip ensuring accurate dosing and ease of administration.

What is Dapagliflozin 5 mg

Dapagliflozin belongs to the class of SGLT2 inhibitors and is indicated specifically for the management of type 2 diabetes. The active ingredient dapagliflozin works by selectively inhibiting the SGLT2 protein in the proximal renal tubules which reduces glucose reabsorption and lowers circulating glucose levels. Unlike some other oral antidiabetic agents dapagliflozin does not stimulate insulin secretion making its mechanism of action independent of pancreatic beta‑cell function. This property contributes to a low risk of hypoglycemia when used alone or in combination with low‑dose sulfonylureas.

Uses and Benefits

The primary use of dapagliflozin 5 mg is to improve glycemic control in adults with type 2 diabetes. Clinical studies have demonstrated that it reduces glycated hemoglobin HbA1c by approximately 0.5 to 1.0 percent compared with placebo. In addition to glucose lowering dapagliflozin has shown cardiovascular benefits including a reduction in hospitalizations for heart failure and a modest decrease in systolic blood pressure. The medication also exhibits modest weight loss effects which can be advantageous for patients with obesity or metabolic syndrome. These attributes make dapagliflozin a valuable option when multiple therapeutic goals glycemic control cardiovascular protection and weight management are prioritized.

How It Works

At the molecular level dapagliflozin binds to the SGLT2 transporter on the apical surface of renal tubular cells. By blocking this transporter the drug prevents the reabsorption of filtered glucose back into the bloodstream. The excess glucose is then excreted in the urine leading to a caloric loss of roughly 300 to 400 kilocalories per day at the 5 mg dose. This caloric loss contributes to weight reduction. Moreover the osmotic diuresis caused by glucosuria can modestly lower blood pressure. The drug’s pharmacokinetics allow for once‑daily oral administration with peak plasma concentrations reached within one to two hours after ingestion. Dapagliflozin is primarily eliminated unchanged through the kidneys and dose adjustments are recommended for patients with estimated glomerular filtration rate eGFR below 60 mL/min/1.73 m2.

Dosage Guidelines

The recommended starting dose of dapagliflozin for most adults with type 2 diabetes is 5 mg taken orally once daily regardless of meals. The dose may be titrated to 10 mg once daily based on glycemic response and tolerability but the 5 mg strength remains the most commonly prescribed initial dose. In patients with moderate to severe renal impairment eGFR 30 to 59 mL/min/1.73 m2 the dose should not exceed 5 mg daily. For patients with eGFR below 30 mL/min/1.73 m2 dapagliflozin is not recommended. The tablet should be swallowed whole with a full glass of water crushing or chewing is not advised. Consistency in timing preferably the same time each day helps maintain steady plasma levels and maximizes therapeutic benefit.

Side Effects

Like all pharmaceutical agents dapagliflozin may be associated with adverse effects. The most frequently reported side effects include genital mycotic infections urinary tract infections and polyuria. While most infections are mild and resolve with adequate hydration and topical treatment patients should be instructed to seek medical attention if symptoms such as fever dysuria or persistent itching develop. Rare but serious complications include ketoacidosis particularly in situations of reduced caloric intake dehydration or surgical procedures. Patients should be advised to monitor for signs of nausea vomiting abdominal pain or unusual fatigue which may herald ketoacidosis. Additionally modest increases in serum creatinine have been observed reflecting changes in renal hemodynamics rather than true renal dysfunction.

Warnings and Precautions

Prior to initiating dapagliflozin therapy clinicians should assess renal function hydration status and history of urinary tract infections. Caution is advised in patients with a prior episode of diabetic ketoacidosis those undergoing surgery or individuals who are pregnant or breastfeeding. Concomitant use of other SGLT2 inhibitors or insulin secretagogues may increase the risk of hypoglycemia dose adjustments are therefore necessary. Patients should be instructed to maintain adequate fluid intake especially in hot weather or when engaging in vigorous physical activity to reduce the likelihood of volume depletion. Finally regular monitoring of renal function and electrolytes is recommended at intervals determined by the prescribing clinician.

Frequently Asked Questions

1. Can dapagliflozin be used as monotherapy for type 2 diabetes Yes clinical guidelines support its use as monotherapy when lifestyle modification alone is insufficient but many clinicians combine it with metformin for enhanced glycemic control
2. How does dapagliflozin affect cardiovascular risk Large outcome trials have demonstrated a reduction in hospitalization for heart failure and a modest improvement in cardiovascular mortality especially in patients with established cardiovascular disease or chronic kidney disease
3. Is dose adjustment required for elderly patients Elderly individuals may start at the standard 5 mg dose but clinicians should monitor renal function and hydration closely as age‑related declines in kidney function are common
4. Can dapagliflozin cause weight loss Yes the glucosuric effect leads to caloric loss resulting in an average weight reduction of 2 to 3 kilograms over six months in many patients
5. What should I do if I miss a dose If a dose is missed it should be taken as soon as remembered unless it is near the time of the next scheduled dose in that case the missed dose should be skipped and therapy resumed at the regular interval

For additional scientific information refer to resources such as the National Center for Biotechnology Information the U.S. Food and Drug Administration and MedlinePlus

Related Products

• Tretinoin 0.025% Cream (TRETINOIN)
• Azelax Cream (Azelaic Acid)
• Tretinoin 0.1% Cream (Tretinoin)
• Tretinoin Cream
• Tretinoin 0.05% Cream (TRETINOIN)
• Accufine 40 mg (Isotretinoin)
• Accufine 30 mg (Isotretinoin)
• Tretiheal 0.025% Cream (Tretinoin)
• Tretiheal 0.05% Cream (Tretinoin)
• Tretiheal 0.1% Cream (Tretinoin)
• Accufine 5 mg (Isotretinoin)
• Accufine 20 mg Softgel Capsule (Isotretinoin)